No headlines found.
No press releases found.
No news found.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Anebulo Pharmaceuticals trades on the NASDAQ stock market under the symbol ANEB.
As of May 13, 2024, ANEB stock price was flat at $3.01 with 95 million shares trading.
ANEB has a market cap of $78.06 million. This is considered a Micro Cap stock.
Last quarter Anebulo Pharmaceuticals reported $0 in Revenue and -$.11 earnings per share. This met revenue expectation and missed earnings estimates by -$.01.
In the last 3 years, ANEB stock traded as high as $9.33 and as low as $1.62.
The top ETF exchange traded funds that ANEB belongs to (by Net Assets): VTI, VXF, IWC.
ANEB has outperformed the market in the last year with a price return of +29.2% while the SPY ETF gained +27.9%. ANEB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.4% and +11.3%, respectively, while the SPY returned +4.3% and +2.6%, respectively.
ANEB support price is $2.79 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANEB stock will trade within this expected range on the day.